Epigenetics and Lead Neurotoxicity by Xu, Yi et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
125,000 140M
TOP 1%154
5,000
1Chapter
Epigenetics and Lead 
Neurotoxicity
Yi Xu, Tian Wang and Jie Zhang
Abstract
Lead exposure continues to threaten human health in a worldwide perspective. 
Among the multiple target organs affected by lead, central nervous system (CNS) 
pervades in the adverse consequences by chronic lead exposure, leading to a variety 
of neurotoxic manifestations and neurological disorders. The epigenetic machin-
ery plays a vital role in the control of key neural functions, particularly neuronal 
development. Faulty epigenetic gene regulation can have marked deleterious effect 
on the developing brain that can last for an entire lifespan. Mounting evidence 
suggests that lead exposure can pose detrimental effect on CNS through these 
epigenetic mechanisms. And this chapter reviews the current understandings of 
concrete epigenetic forms, exemplified by DNA methylation, histone modification, 
and ncRNAs, responding to lead exposure and moderating the consequent neu-
rotoxicity. In addition, Alzheimer’s disease (AD) is presented as a typical instance 
to explain how environmental lead exposure results in the occurrence of AD in an 
“early exposure, late onset” fashion. A future perspective, highlighting additional 
forms of epigenetic elements as well as interactive actions among different mol-
ecules, was also proposed. In summary, epigenetics was substantially implicated in 
regulating lead neurotoxicity.
Keywords: epigenetics, lead neurotoxicity, DNA methylation, histone modification, 
ncRNA, Alzheimer’s disease
1. Introduction
Lead (Pb) is a ubiquitous and persistent neurotoxicant that continues to threaten 
human health in a global perspective [1]. Although lead has been removed from 
paints and gasoline, it remains a serious concern as it can still be found in a variety 
of daily products, including toys, batteries, food, and water [2]. Although Pb 
poisoning is a preventable disease, thousands of new cases in the United States 
were reported each year, and about 500,000 children under 5 years old have blood 
lead levels (BLLs) greater than a threshold level of 5 g/dl, according to Centers for 
Disease Control and Prevention (CDC) reports [3–7]. Elevated BLLs have become 
the first noninfection condition to be notifiable at the national level [7]. Lead can 
cause a series of adverse human consequences at a very low level exposure [8]. 
Therefore, CDC continually decreased the safe threshold of BLLs, and the current 
“safe” levels of exposure to lead are 5 mg/dl for children, but still there have been 
studies to identify cognitive impairments below that dosage, implying that “no level 
of lead exposure is safe” [6, 9].
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Lead pervades many organs and systems in the human body, but the prime target 
of lead toxicity is CNS, both in adults and in children [10], resulting in the so-called 
“neurotoxicity.” The developing brain is particularly susceptible to lead neurotoxicity, 
as demonstrated by several epidemiological and experimental studies [2, 3]. Due to 
the fact that lead can freely cross blood brain barrier, lead neurotoxicity can also be 
manifested in adults, with a larger exposure dosage. Particularly, it should be note-
worthy that early life exposure to lead can produce persistent alterations in the brain 
structure of adults, causing lasting impairment of brain function and behavior [3, 11]. 
Adverse neurotoxic effects caused by lead include intellectual and behavioral deficits 
in children; deficits in fine motor function and coordination; and deficits in lower 
performance on intelligence tests [10]. Higher level of lead can cause a wide spectrum 
of neurological disorders, such as convulsions and coma, including multiple instances 
of neurodegenerative disorders, such as AD and Parkinson’s disease [12–15]. Thus, 
there is a critical need to understand the mechanisms of lead neurotoxicity.
Among the cellular and molecular mechanisms suggested to underlie lead 
neurotoxicity, amounting evidence underscored roles of epigenetic molecules. 
This fast-moving filed of epigenetics has opened a novel avenue of research for 
understanding how environmentally toxic signals like lead exposure could be 
readily sensed by organisms and then relayed to reprogram the expression of key 
functional genes, consequently giving rise to neurotoxic manifestations [3, 16–19]. 
This chapter is aimed to discuss the advances of epigenetic alterations in response to 
lead-induced neural deficits, focusing on the concrete epigenetic species and their 
responsive details. We will also present a synoptic view of epigenetic implications in 
etiology of AD caused by long-term lead exposure and bring out the possible future 
perspectives of the related research topics.
2. Molecular mechanism of lead-induced neurotoxicity
Since lead was found to mediate severe neurological impairment toward both 
children and adults, myriad studies were appreciated to decipher the cellular and 
molecular alterations underlying this neurotoxic incident. Several routes of action 
have been most commonly proposed, such as oxidative stress, disruption of blood 
brain barrier, decreased cellular energy metabolism, deregulation of calcium signal-
ing, and abnormal neural transmission [3, 20]. In terms of relevance to neuronal 
development and synaptic transmission, postsynaptic mechanisms represented by 
N-methyl-D-aspartate receptor (NMDAR), presynaptic mechanisms, and brain-
derived neurotrophic factor (BDNF) signaling were shown to be involved in lead 
neurotoxicity [8, 21].
NMDR plays an essential role in hippocampus-mediated learning and 
memory, and its dysfunction is associated with spatial learning abnormalities, as 
well as dendritic atrophies [22]. Lead regularly disrupted NMDAR function by 
acting as a potent antagonist. Apart from it, lead exposure also disrupts normal 
NMDAR ontogeny, such as reducing NR2A content, altering expression of NR1 
splice variants [23, 24].
Chronic lead exposure also results in impaired neurotransmission. A previous 
finding showed that chronic lead exposure reduced Ca2+-dependent glutamate and 
γ-aminobutyric acid (GABA) release in the rat hippocampus [25, 26]. And in cultured 
hippocampal neurons, lead exposure was found to impair excitatory postsynaptic 
currents (EPSCs) and inhibitory postsynaptic currents (IPSCs) [27]. Our lab recently 
published a finding that chronic lead exposure can inhibit the release of neurotrans-
mitters by interfering with its vesicle pool recycling, and the main protein impacted is 
synapsin 1, which expression and phosphorylation was prone to lead invasion [28].
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An emerging theme involved in lead neurotoxicity is the disruption of brain-
derived neurotrophic factor (BDNF) expression. BDNF is a trans-synaptic signaling 
molecule that is released from both dendrites and axons [29]. In response to lead 
exposure, BDNF levels in cell cultures were downregulated, and the exogenous 
addition of BDNF can rescue the deleterious effect of Pb [30]. As a regulator of Ca2+ 
signaling and homeostasis, BDNF perturbation in turn led to the disrupted Ca2+-
dependent pathways, which compromise severe neural representations caused by 
lead exposure [31]. As an alternative consequence, lead impaired the hippocampal 
dendritic spines, reduced their density, and changed their morphology [32].
These neuronal and molecular processes might reflect variable aspects of 
lead-induced neurotoxicity. Compared to it, roles of global regulators, such as the 
emerging epigenetic regulators, are not sufficiently understood. However, given 
the conformity with outstanding characteristics of lead neurotoxicity, like “early 
exposure, persisted effect,” epigenetics was long hypothesized to be implicated in 
the etiology of lead-induced psychological disorders [3]. This was supported by 
further identification of lead exposure as a risk factor of Alzheimer’s disease and 
schizophrenia. Our next section will focus on epigenetic determinants involved in 
lead-led neurological damages and diseases [33, 34].
3. Epigenetic mechanisms
Epigenetics is defined as the heritable changes in gene expression that are not 
related to alterations in the genetic code [3]. Epigenetic regulation is found to 
modify the conformational state of chromatin and the accessibility of specific gene 
promoters to the transcriptional machinery [14]. There are three main epigenetic 
mechanisms broadly studied: DNA methylation, posttranslational modifications of 
histones, and noncoding RNA (ncRNA) [35–37]. The basic modes of action of three 
epigenetic forms were shown in Figure 1. DNA methylation is the most-studied 
epigenetic mechanism, which involves primarily cytosine methylation of Cytosine 
Guanine dinucleotides (CpG) via DNA methyltransferases (DNMTs). CpG methyl-
ation is often linked with transcriptional inhibition as it interferes with the normal 
binding and activity of transcription binding proteins [38]. The exception to this 
is CpG islands, which are CpG-rich sequences that are densely populated with 
unmethylated CpGs [2]. CpG islands offer the possibility of being differentially 
regulated by the environmental signals, which are a prime site to study the influ-
ence of lead on epigenetic determinants of ensuing neurotoxic phenotypes [39].
Gene expression is also regulated by histone modifications [36]. Histones are 
alkaline proteins that wrapped around DNA in nucleosomes and moderated gene 
transcription by modulating chromatin compaction and accessibility [40]. The 
terminal tails of histone can undergo covalent posttranslational modifications 
(PTMs), which in turn alter their interaction with DNA. Diverse modification 
forms were discovered and studied, as well as their influence on transcription 
of objective genes, including acetylation, phosphorylation, methylation, and 
ubiquitination [2]. The complex forms of histone modifications could coexist 
in regulating a common gene or genome, establishing an intricate and complex 
regulatory network called “histone code” [41, 42]. The proposal of this definition 
opens an avenue to show the potential accuracy and delicacy of gene expression 
regulation, via the action of histone modifications, which are operated by cor-
responding enzymes, such as histone acetyltransferases, histone deacetylases, 
histone methylases, and histone demethylases. Among them, histone deacetylases 
have been widely studied and identified as key molecular targets for pharmaceu-
tical interventions [43, 44].
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Another layer of epigenetic regulation involves noncoding RNAs (ncRNAs), 
defined as functional RNA molecules that are not translated into proteins [3]. 
The category of ncRNA with relevance with epigenetic regulation is composed of 
microRNA (miRNA), lncRNA, piRNA, and snoRNA, which regulate gene expres-
sion at both transcriptional and posttranscriptional levels [37]. miRNA received the 
most attention among them, and details of miRNA types involved in various epigen-
etic regulation and neuronal processes were studied comprehensively. For instance, 
a recent publication revealed that a series of miRNAs can respond to and mediate 
spinal muscular atrophy pathogenesis [45]; miR-137 participated in the modulation 
of neuronal maturation by targeting an ubiquitin ligase mind bomb-1 [46].
The different forms of epigenetic regulation are often functionally interlaced, 
showing an interactive relationship. DNA methylation was commonly accompanied 
by a specific form of histone methylation, establishing a so-called “hand-in-hand” 
Figure 1. 
Types of epigenetic modifications. (A) CpG methylation; (B) histone modifications represented by acetylation 
and methylation; (C) biogenesis and inhibitory action of microRNA (miRNA).
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assembly [47]. Histone deacetylase can be recruited by DNA methylation or its 
functional partner, and these molecules can cooperate with each other to determine 
(most commonly inhibit) the expressional status of the objective gene [48]. DNA 
methylations and histone modifications are both involved in establishing patterns 
of gene expression, and they may play distinct roles in inducing persistent or 
intermittent gene expression changes [14].
Epigenetic mechanisms are implicated in neuronal development, maintenance 
of cell identity, and aging process [49, 50]. Meanwhile, epigenetic perturbations 
that lead to chromatin remodeling are in association with a number of neuropsy-
chiatric and neurodegenerative disorders [14, 51], and they are particularly relevant 
in response to environmental toxicant exposure early in life [38]. The impact of 
epigenetic determinants can be long lasting, or even transgenerational, that is, the 
epigenetic traits and gene expression patterns can be sometimes inherited by next 
generations, which are not previously exposed to the causative agents [52].
4. Lead-induced epigenetic alterations in CNS
Considering that epigenetic factors are associated with CNS functioning and 
meanwhile susceptible to environmental exposure, we next discuss the epigenetic 
outcome brought by lead exposure and the roles of these changes in the etiology and 
development of lead neurotoxicity.
The relations of lead exposure with neural epigenetic alterations have long been 
established. Developmental lead exposure results in a variety of epigenetic changes, 
characterized by DNA methylation alterations, which can impact gene expression 
patterns and affect nervous system development [5]. Lead can promptly affect the 
dynamism of epigenetic determinants and promote the rapid turnover of DNA 
methylation [4]. Consistent with these findings and statements, lead is known to 
be an epigenetic modifier [53]. The following are advances of three main epigenetic 
systems associated with lead neurotoxicity:
4.1 DNA methylation
Lead exposure can result in the global changes of DNA methylation profiles 
in CNS, and the detailed orientation of methylome changes varied depending on 
the studied genetic microenvironment. Singh et al. stated that developmental lead 
exposure disrupted the hippocampal methylome, and the effect is dependent on the 
gender, timing, and level of exposure [5]. In particular, the global methylome altera-
tions did not reflect the methylation status of the specific genes. That identified low-
level lead exposure as a causative agent of gene-specific DNA methylation patterns 
in brain [54]. Senut et al. found that lead exposure disrupts global DNA methylation 
in human embryonic stem cells and alters their neuronal differentiation [4]. An epi-
demiological study investigated 105 children participants from birth to 78 months 
and tested peripheral blood DNA to quantify CpG methylation at Differentially 
Methylated Regions (DMRs) of 22 human imprinted genes. This study provided 
evidence that early childhood lead exposure resulted in gene-specific DNA methyla-
tion differences in the DMRs of PEG3, PLAGL1/HYMAI, and IGF2/H19 [51]. In 
2009, Pilsner et al. published the first human study to reveal that maternal bone lead 
levels were associated with changes in DNA methylation levels in the umbilical cord 
blood leukocytes of the offspring [55]. In animal studies, DNA methylome-related 
genes, including DNA methyltransferases, methyl-cytosine-phosphate-guanine 
(Me-CpG) binding protein-2 (MeCP2), and methionine synthase, were recognized 
as the potential targets of lead exposure [56, 57]. Sanchez-Martin et al. reported 
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that lead exposure resulted in hypermethylation of three differentially methylated 
regions in the hippocampus of females, but not males [11]. Overall, lead is a strong 
environmental force to globally reshape DNA methylation landscape in brain, which 
is a susceptible organ for epigenetic regulations.
Apart from methylome, the gene-specific alterations of methylation may reflect 
the detailed influence of lead exposure in CNS. Zawia et al. examined the activity 
of DNA methyltransferase in the tissues of 23-year-old primates exposed to lead 
as infants. As a consequence, they found that activity of this methylation enzyme 
was selective for cytosine nucleotides in a CpG sequence and specific to ones that 
base-paired to methylated CpG sequence on the other DNA strand [25]. Some genes 
triggered during memory formation and synaptic plasticity, such as BDNF, showed 
marked changes in promoter methylation when DNMT activity is suppressed in 
mice hippocampus, indicating that BDNF can be potentially modulated by speci-
fied DNA methylation status [58]. Wu et al. investigated the association between 
prenatal maternal lead exposure and epigenome-wide DNA methylation. Among 
female infants, one CpG (cg24637308) showed a strong negative association with 
lead levels, and this CpG site was thought to be highly expressed in human brain 
[59]. Our previous study also measured CpG methylation levels in specific CpG-
rich promoter regions of DAT1 and DRD4, two dopaminergic-related genes, in the 
children with higher blood lead levels. According to it, a specific CpG site located 
upstream of DRD4-coding region was found to be hypermethylated due to lead 
exposure, and this changes were negatively correlated with the expression levels of 
DRD4 [39]. The relevant literature pertaining to associations of lead neurotoxicity 
and DNA methylation was summarized and shown in Table 1.
A number of reports suggested that alteration in DNA methylation was largely 
gender- and tissue-dependent [73]. Early life lead exposure of 3 and 30 ppm led to 
gender-specific DNA hypermethylation at Rn45a and Sfi1 genes in the hippocampus 
of female mice only [11]. Another study also stated that maternal lead exposure 
caused gender-specific epigenetic outcomes for varying degree of vulnerability later 
in life [74]. These gender differences might be related to the action of sex hormone 
and the structural discrepancies of body structure resulting in the variance of lead 
metabolic routes.
CpG methylation was reprogrammed through the action of DNA methylases. 
Amounting evidence suggested that this pathway was utilized by lead to bring 
adverse neurological outcome. In a 23-year-old primate with early exposure of 
lead, protein levels of DNMTs and MeCP2 were significantly decreased. And this 
attenuation was consistent with hypomethylating effects at multiple genetic loci 
[14]. Another report found a decreased DNA methyltransferase activity in mouse 
cortical neuronal cells exposed to lead for 24 h and determined later in life [16]. In 
a mouse study with developmental lead exposure, DNMT3a in male mice displayed 
increased expression with 150 and 750 ppm of Pb, while female mice had decreased 
expression of DNMT3a in response to 150 and 375 ppm of Pb. Moreover, devel-
opmental lead exposure can also affect the expression of DNMT1 and MeCP2 in 
murine hippocampus, which gender and exposure periods were critical contribut-
ing factors [57]. Therefore, both expression levels and enzymatic activities of 
methylation-modifying enzymes can be modulated by lead exposure in CNS.
Except from a conventional methylation form, 5-hydroxymethylated cytosine 
(5hmC), a new modification and mostly implicated in promoting gene expression, 
was recently known to be altered by lead exposure in CNS. 5hmCs was extremely 
abundant in rodent brains, and they are closely associated with critical neurodevel-
opmental processes such as neuronal differentiation and synaptic function [75]. In 
light of it, Sen et al. reported that prenatal exposure to lead can alter the hydroxy-
methylation profile of 5hmC-riched clusters of imprinted genes, which resulted in an 
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Animal (Age) Exposure 
duration
Epigenetic 
mechanisms
Pathophysiological 
outcomes (possible)
References
Human 
embryonic 
stem cell
A: day 1
B: day 5
C: days 0–19
D: days 11–19
DNA methylation status 
of genes crucial to brain 
development
Exposure to Pb subtly 
alters the neuronal 
differentiation of 
exposed hESCs
[4]
Newborns 
(prenatal)
Prenatal DNA methylation 
at LINE-1 repetitive 
elements; UCB LINE-1 
methylation
Epigenetic 
alterations have 
detrimental effects 
on the developing 
brain, neurological 
development, and 
disease
[38]
Newborns From birth  
to 78 months
DMR methylation 
for PEG3 (A), IGF2/
H19 (B), and HYMA/
PLAGL1 (C)
Sex-dependent and 
gene-specific DNA 
methylation
[51]
Mice (10 
months)
2 weeks 
prior mating 
and during 
gestation 
and lactation 
until PND21
Average brain 
methylation: IAP 
110:80%
Neurodegeneration, 
narcolepsy
[60]
Mice (PND 20 
and 700)
Gestational 
D13 until 
PND20
DNA hypermethylation Gene repression in 
old age
[61]
Rats (PND55) 10 days prior 
breeding till 
weaning of 
55D
↓DNMT1 with postnatal 
150ppm Pb
↓DNMT1 with postnatal 
375ppm Pb
↑DNMT1 with postnatal 
750ppm Pb
↓DNMT1 will all 
perinatal Pb
Defects in neuronal 
maturation, synaptic 
plasticity, learning, 
memory, cognition, 
and behavior
[57]
Mice (PND20 
and PND700)
Gestational 
D13 until 
PND20
501 downregulated 
genes and 647 
upregulated genes
Affecting immune 
responses, metal 
binding, metabolism, 
transcription, and 
transduction
[56]
Mice (PND1 to 
PND20)
PND1 to 
PND21
↑Dlx1 methylation
↓Gene expression of 
Dlx1/2/5/6
↑Gene expression of 
Tubb3
Hyperactivity, weight 
loss, abnormal 
behavior
[62]
Monkeys  
(23 years)
Birth until 
400D
↓DNMT1
↑APPmRNA
↑Aβ1-40mRNA
↑Aβ1-42mRNA
Alzheimer’s disease [16]
Mice  
(2 months)
2 months 
prior mating 
and during 
gestation 
and lactation 
until PND2
Hypermethylation in: 
Rn4.5s
loci in chromosome2
Sfi1 loci in 
chromosome11
(Rn45s loci 
inchromosome17)
DNA methylation 
(sex and tissue 
specific)
[11]
Lead Chemistry
8
Animal (Age) Exposure 
duration
Epigenetic 
mechanisms
Pathophysiological 
outcomes (possible)
References
Mice (PND0 
and PND6)
2 months 
prior 
breeding and 
throughout 
lactation
↓H3K9/14Ac:b/w PND0 
& PND6 (HPC)
↓ H3K9Me3:b/w PND0 
& PND6
↓H3K9/14Ac
↓H3K9Me3
↓H3K9/14Ac: 50% at 
PND0
with 100ppm Pb
↑H3K9/14Ac: 60% at 
PND0
with 100ppm Pb
Weight loss, 
abnormal brain 
development and 
cognitive function 
(sex, age, and brain 
region specific)
[63]
Rats Perinatal to 
60D
Acetylated H3 in 
hippocampus
↑p300 (HAT) mRNA
↑HDAC1 mRNA
Hyperactivity, 
behavioral disorder, 
neurological 
disorder, ADHD 
(dose specific)
[64]
Monkeys 
(3–6,12,23 
years)
Birth until 
400D
Altered gene expression 
(22)
↑APP mRNA and 
protein
↓Dnmt3a and Dnmt1 at
23years
↓MeCP2 at 23years
↑H3K9ac, H4K8ac, 
H4K12ac
↑H3K4me2
Neurodegeneration 
in old age, up and 
downregulation of 
genes
[14]
Mice  
(Weeks 20)
E1 to E10 Hypomethylated Chd7 
gene
↑Chd7 gene expression 
(4.7 folds) Altered 
histone methylation
Autism-like behavior, 
multiple behavioral 
abnormalities
[65]
Mice (PND20, 
180,270, 540, 
and 700)
PND1 to 
PND20
↓DNMT1 protein
↑DNMT3a mRNA at 
PND20
↓MeCP2 at PND20 and 
270
↑MAT2A at PND270, 
540 and 700
↓H3K9Ac protein at 
PND700
↓H3K4Me2 protein at
PND20
Alzheimer disease [15]
Transgenic 
mice (15)
(PND20, 30, 
40, and 60)
PND1 to 
PND20
Hyperphosphorylation 
(internal and external 
brain capsule)
↑ miR34c expression 
b/w PND20 and 50
↑ tau mRNA at PND20
↑CDK5 mRNA at 
PND40
↑ Total tau protein at 
PND20 and 40
↑CDK5 protein at 
PND40 and 60
↑ Phosphorylated 
tau Ser396 protein at 
PND20 and 30
Alzheimer’s disease, 
tauopathies
[66]
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Animal (Age) Exposure 
duration
Epigenetic 
mechanisms
Pathophysiological 
outcomes (possible)
References
Mice (PND20, 
180 and 700)
PND1 to 
PND20
↑miR-106b at PND20 
(1.5 fold)
↓ miR-34c at PND180 
(1.6 fold)
↑miR-29b at PND20 (1.6 
fold)
↑ miR-132 at PND20 
(4.8 fold)
↓miR-124 at PND700 
(2 fold)
Alzheimer’s disease, 
tauopathies
[67]
Rats (20–22 
days)
8 weeks ↑miR-211 with 300ppm 
Pb (1.75 old)
↓ miR-494 with 
300ppm Pb (2.04 fold)
↑miR-449a with 
300ppm Pb (2.89 fold)
↑miR-34c with 300ppm 
Pb (4.05 fold)
↑miR-34b with 300ppm 
Pb (4.48 fold)
↑miR-204 with 300ppm 
Pb (5.48 fold)
↑miR-448 with 300ppm 
Pb (30.51 fold)
↓mRNA with 300ppm 
Pb (Bcl2, Itpr1)
↓mRNA Map2k1 with 
300ppm Pb
Neural injury, 
neurodegeneration, 
axon and synapse 
dysfunction, 
impaired neural 
development and 
regeneration, 
impaired 
performance, 
Alzheimer’s disease, 
Parkinson’s disease 
and depression
[68]
Rats (2-4 
weeks and 
12–14 weeks)
40D Apoptotic cells with 
irregular nuclear 
membrane, chromatin 
clumping, and nuclear 
fragmentation
Apoptosis [69]
Mice  
(10 months)
2 weeks 
prior to 
mating and 
continued 
throughout 
gestation to 
3 weeks after 
birth
ARTN & C5aR1 
methylation
32 ppm Pb exposure )
Ankdd1b methylation
2.1 ppm Pb exposure)
Death of neurons, 
Alzheimer’s disease, 
migraine, and major 
depressive disorder
[70]
Rat (PND55) PERI: 10 
days prior to 
breeding to 
PND 21
EPN: birth 
through 
weaning 
(PND 21)
LPN: birth 
through 
postnatal 
day 55
Quantities of 
methylation changes at 
gene promotor region 
and varies according to 
genders
Schizophrenia, 
Alzheimer’s disease, 
memory impairment, 
etc.
[5]
Mice (E18, 
PND0, PND6, 
and PND60)
2 months 
prior to 
breeding and 
throughout 
lactation
Changes of H3K9Ac, 
H3K4Me3,
H3K9Me2, H3K27Me3 
level
Cognition deficits, 
behavioral 
dysfunction, 
neurodevelopmental 
disorders
[71]
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altered expression of objective genes in a gender-dependent manner. 5hmC may also 
serve as potential biomarkers for lead susceptibility to neurological diseases [76].
As a general rule, the changes of DNA methylation levels were often negatively 
correlated with the transcription levels of the objective genes. But this association 
was dependent on gender, the exposure periods, and their relative genetic locations. 
Interestingly, for females, genes regulated by DNA methylation were inclined to 
encode RNA- and protein-related processes; and for males, the enriched pathways 
included signaling pathways, stress, and neural responses to stimuli [5].
4.2 Histone modification
Compared to DNA methylation, fewer associations between histone modifica-
tion and lead neurotoxicity were reported. Categorized by posttranslational forms, 
most studies focused on histone acetylation changes in response to lead exposure. A 
specific histone acetylation level results from the balanced counteraction of histone 
acetyltransferases (HATs) and histone deacetylases (HDACs). An acetylated form 
normally corresponds to a more relaxed chromatin status, leading to an enhanced 
expression of the target genes, and vice versa [77]. In 2014, our lab published a rela-
tively novel article describing an increased acetylated form of histone H3 as exposed 
by 5 or 25 mg/l of lead. This alteration accompanies with the enhanced transcription 
of p300, a typical HAT [64]. Subsequently, the interesting point is that chronic lead 
exposure reduced the total level of H3K9ac, displaying an opposite tendency to total 
H3ac levels, which unveiled a specific alteration depending on the concrete acetyla-
tion sites, as well as the neural models and exposure conditions used [78].
Some innovative progresses were made in the primates with early life exposure. 
Bihaqi et al. observed that apart from DNMTs and MeCP2, lead also caused lifelong 
alterations of H3K9ac, H3K8ac, and H4K12ac, which levels were increased only in 
23-year-old adults, not in 12-year-old primates [14]. In another instance, perinatal 
lead exposure downregulated H3K9ac levels in aging mice, a proof that key epigen-
etic regulators can be linked with development of Alzheimer’s disease [15]. Murine 
hippocampus and frontal cortex were similar in lead-induced epigenetic changes, 
that is, H3K9/14ac was gradually reduced as exposure prolonged, factored by mixed 
actions of gender and prenatal stress [63]. The literature pertaining to histone 
modifications and lead neurotoxicity was shown in Table 1.
Animal (Age) Exposure 
duration
Epigenetic 
mechanisms
Pathophysiological 
outcomes (possible)
References
Mice (PND0 
and PND6)
Pb acetate 
for 2 months 
prior to 
breeding 
until sacrifice
Changes of H3K9/14Ac 
and H3K9Me3 level
Cognitive/behavioral 
problems during 
childhood
[63]
Mice (PND20 
and PND50)
PND 1 to 
PND 20
↓MECP2
↑Dnmt3a mRNA & 
miR-29b (PND50)
↓DNMT1 mRNA 
(PND50)
↑miR-148a(PND50)
↑SP1 mRNA(PND20)
↑miR-124(PND50)
↓APP mRNA(PND20)
↑miR-106b(PND50)
Tau-induced cell 
apoptosis in AD; 
neurodegeneration
[72]
Table 1. 
Summary of some literature concerning epigenetic changes involved in lead neurotoxicity.
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Different from histone acetylation, histone methylation gained a stricter site 
specificity and more stable to maintain gene expression patterns [79]. With the 
developmental exposure of lead, primates of 400-day olds were subjected to 
epigenetic examination in brains. H3K4me2 was found to be increased significantly, 
indicating an activated propensity of related gene expression [14]. In another ani-
mal study, H3K9me3 displayed a relatively stable tendency with treatment of lead 
in mice, and those cases varied depending on the studied brain regions and genders 
[63]. According to general knowledge gained in this field, H3K4me basically played 
roles in promoting gene expression, while H3K27me and H3K9me mostly displayed 
negative regulatory activity. Our previous finding underpinned the importance 
of H3K27me3 in modulating lead-induced spatial memory deficits [80]. We found 
that chronic lead exposure perinatally could reduce the global H3K27me3 levels in 
rat hippocampus, and this alteration led to a genome-wide reprogramming of this 
repressive epigenetic mark on the target genes. This result gave a picture of how an 
epigenetic change can give rise to a global genetic response and the ensuing adverse 
neurological outcomes.
In contrast with acetylation and methylation, very few studies were shown to 
investigate the interaction of lead neurotoxicity and other forms of histone modifica-
tions. In spite of deficiency of relevant literature, this study is supposed to be promis-
ing to totally decipher histone codes involved in lead neurotoxicity. H2A ubiquitination 
was recently found to be associated with DNA damage response, which suggested that 
site-specific histone ubiquitination organizes the spatiotemporal recruitment of DNA 
repair factors, and these recruitments facilitated DNA repair pathway choice between 
homologous recombination and nonhomologous end joining [81].
4.3 ncRNA
ncRNAs are epigenetic regulators susceptible to environmental signals. Among 
diverse forms of ncRNAs, microRNA (miRNA) was most extensively studied con-
cerning their relations with lead neurotoxicity. In rats chronically exposed to lead, 
at least seven miRNAs were altered considering their expression levels. In details, 
miR-204, miR-211, miR-448, miR-449a, miR-34b, and miR34c were dramatically 
upregulated, while miR-494 was downregulated. These miRNAs were implicated in 
regulating genes involved in neurodegeneration, synaptogenesis, and neuronal injury 
[68]. Masoud et al. observed that early life lead exposure yielded a transient increase 
in the expression of AD-related miRNAs, such as miR-106b, miR-29b, and miR-132 
[67]. Another rat exposure model with 100 ppm Pb also gave some evidence that some 
miRNAs, mainly targeting to a histone methyltransferase EZH2, were divergently 
regulated by lead in pup hippocampus. In response to lead, abundance of miR-137 and 
miR-101 was elevated, and miR-144d was decreased. The aberrant stimulation miR-
137 may have important physiological relevance, as it formed a negative regulatory 
loop with EZH2, which drove the downregulation of H3K27me3 [80]. Some examples 
of miRNA changes during lead-induced neurotoxicity were shown in Table 1.
It is insufficient for other forms of ncRNAs remodeled by lead exposure in 
CNS. In 2018, Nan published an interesting article with relevance to this research 
field [82]. The authors identified a novel lincRNA (long noncoding RNA), namely 
lncRNAL20992, as a key responsor toward lead neurotoxicity. lncRNAL20992 was 
significantly upregulated in a lead-induced neuronal injury model. Four proteins 
were found to physically interact with lncRNAL20992 to mediate the lead-induced 
neuronal injury. To date, few associations of piRNAs or circRNAs were discovered 
with lead-induced neurotoxicity. Interestingly, a 98-nucleotide nuclear RNA with 
unknown function called Rn4.5s, as well as a RNA precursor Rn45s, showed changes 
in methylation in the hippocampus of females exposed to 3 ppm of lead [11].
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5. Epigenetic mechanisms of lead-induced Alzheimer’s disease
By modifying the global epigenetic landscape, early life lead exposure had not 
only immediate adverse consequences for brain development but also persistent 
effects till the later life. This toxic property may increase the susceptibility of 
organisms to diseases, especially CNS-related diseases [3]. It has been long estab-
lished that chronic lead contact is an important risk factor for the pathogenesis 
of Alzheimer’s disease [83]. This finding is significant because AD is the most 
common form of dementia, which affects aging individual. There were at least 
25 million people worldwide affected by this disease in 2003, including at least 
4.5 million people in the United States [84]. Similar to other neurodegenerative 
diseases, AD is a complex and heterogeneous disorder with both environmental 
and genetic etiology.
There are a variety of molecular mechanisms proposed to mediate the lead-
induced pathogenesis of AD. In monkeys, Wu et al. discovered that with lead 
exposure in infants, the aging monkeys exhibited abnormal expression alterations 
of AD-related genes and a key transcriptional regulator specificity protein 1 (Sp1). 
This was manifested by increasing AβPP, b-site AβPP cleaving enzyme (BACE), and 
Aβ and by decreasing DNA methyltransferase activity [16]. In an epidemiological 
review toward the Mexican population, it was summarized that early-life lead expo-
sure was a potential risk factor for AD in the Mexican population [85]. While these 
mechanisms partly explained the key cellular and molecular changes brought by 
lead exposure, it is still pivotal to figure out the “fetal programming” phenomenon 
involved in the studied pathogenesis.
Roles of epigenetics are much appreciated due to their similar modes of 
action with “fetal origin of adult disease,” which characterizes the basic regulari-
ties underlying lead-induced pathogenesis of AD [3, 11]. One anticipated way 
to achieve long-lasting or permanent changes in gene expression is to alter the 
structural makeup of the DNA bases that led to hypermethylation or hypomethyl-
ation consequences. The changes of DNA methylation in promoters or other gene 
regulatory components are found to be extremely stable and can even transmit-
ted to the next generation. This style of action is consistent with the neurotoxic 
course of Pb to induce AD and is anticipated to fetal program the key AD-related 
genes, enabling their long abnormal transcriptions. Compared to CpG methyla-
tion, histone modifications are normally unable to elicit permanent regulatory 
effect till aging period, as evidenced by previous findings that H3K9ac and 
H3K4me2 followed lifespan-dependent changing curves, whereas variable time 
points showed different altering orientations [15]. Therefore, CpG methylation 
might be a competent epigenetic mechanism of choice to be used to explain the 
long development of AD. In another aspect, susceptible response from specific 
histone modification may be used to early predict the risk of AD, on the basis of 
their potential genetic associations.
Given these observations, White et al. proposed the possible pathways by 
which epigenetic factors mediate Pb-led pathogenesis of AD (Figure 2) [25]. They 
regarded epigenetics, mainly represented by CpG methylation, as potential key 
mechanisms that manifested delay consequences of lead exposure and consequent 
Alzheimer’s disease. According to this hypothesis, early-life lead exposure caused 
a cascade of molecular changes exemplified by reducing CpG methylations at 
promoters of key AD-related genes, such as APP and BACE. Assisted by the actions 
of MeCP2 or SP1, these methylation reductions promoted the gene expression 
toward the corresponding proteins. Subsequently, Aβ was synthesized and started 
to accumulate in the later life. When the accumulation reached to a threshold value, 
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AD symptoms started to emerge and progress. This hypothesis gives an intriguing 
example to implicate epigenetic factors with Alzheimer’s disease induced by early-
life lead exposure.
6. Conclusion and future directions
In conclusion, epigenetic factors played essential roles in mediating lead-
induced neurotoxicity. Comprehensive investigations unveiled the importance of 
CpG methylations in multiple genetic loci in rodents and primates. CpG methyla-
tion on a specific gene promoter might give rise to a long-term suppression of 
gene expression, in which case formed a phenomenon of “fetal programming” of 
neurological disease. In addition, changes of histone modifications might reflect a 
relatively dynamic signal to moderate the ensuing molecular relay and neurotoxic 
manifestations. As a newly emerging research field, it is anticipated to have several 
future directions about relevant of epigenetic factors to lead neurotoxicity: (1) new 
epigenetic mechanisms, such as 5hmC, RNA methylation, and scarcely mentioned 
ncRNA forms, need to be thoroughly investigated regarding their associations 
with lead neurotoxicity; (2) most previous studies observed the huge impact of 
gender on the neurotoxic performances, but very few explanations were provided. 
Epigenetic differences and causing agents between the genders should be inves-
tigated with insight; (3) there are currently some medicine developed to target 
epigenetic sites, like HDAC inhibitors. However, the sole histone deacetylase is 
Figure 2. 
Possible epigenetic mechanism of Alzheimer’s disease induced by early life lead exposure.
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unable to reflect the global epigenetic aspects and to use for intervention with full 
efficacy. Other specific reversing pharmaceuticals targeting epigenetic factors are 
warranted to be developed to interfere with development of neurological disease 
induced by lead exposure.
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